• Australia’s Genome.One and U.S.-based OneOme have partnered to provide insights into individuals’ genetic risk of disease and pharmacogenomic responses
• The offering is part of Australia’s first whole genome and health assessment service that provides new information to prevent or manage disease
• The service currently identifies genetic risk for 49 conditions and the body’s predicted response to 220 medications

24 June 2017 – Australia’s Genome.One and U.S.-based OneOme have partnered to provide genetic and pharmacogenomic information as part of a new personal health management service launched earlier this month that allows unprecedented insights into the current and future health of Australians.

This service includes genome sequencing provided by Genome.One and pharmacogenomic testing using OneOme’s RightMed test, which identifies how an individual’s DNA affects his or her response to certain medications. A comprehensive health assessment, offered in partnership with Sydney’s Life First, provides additional health and wellbeing information for a more comprehensive picture of an individual’s health.

Dr. Marcel Dinger, CEO of Genome.One, said that the partnership with OneOme is an important component of the company’s service. “Our service can detect a person’s increased genetic risk for more than 49 conditions across more than 230 genes, which helps healthcare professionals to offer advice on how to reduce identified risks. Understanding the body’s response to 220 medications adds important insights into how a condition can be managed.”

The RightMed pharmacogenomic test analyzes an individual’s DNA to better inform prescription decisions by predicting adverse drug reactions and drug effectiveness. It was co-developed and exclusively licensed from Mayo Clinic in the U.S. with the aim of bringing pharmacogenomics into routine clinical care.

Paul Owen, CEO of OneOme said that pharmacogenomics may unlock information about how specific drugs will affect you, based on your DNA. “Your body’s response to medication is determined by many factors, with the largest factor being your genetic makeup. A drug that’s effective for one person may have no effect for another person, or it may cause undesirable side effects. Information from our RightMed test can help healthcare providers make prescriptions more personal.”

“We believe in bringing the benefits of pharmacogenomics to everyone, and we’re thrilled to be partnering with Genome.One to make our service available to more people than ever before.”

The service is delivered by a team of health professionals who can offer expert interpretation to understand what the results mean as well as support and advice on what can be done to reduce identified risks.

Dr Dinger added: “Personal genomic information not only empowers individuals to take control of their health and potentially prevent disease, it can also optimise treatment in the clinic. This is why we believe that this service signals the beginning of a new era in understanding an individual’s health and the prevention and management of disease.”